Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells
Autore:
Kinoshita, Y; Kono, T; Yasumoto, R; Kishimoto, T; Wang, CY; Haas, GP; Nishisaka, N;
Indirizzi:
Osaka City Univ, Sch Med, Dept Urol, Abeno Ku, Osaka 5438585, Japan Osaka City Univ Osaka Japan 5438585 Urol, Abeno Ku, Osaka 5438585, Japan State Univ New York Upstate Med Univ, Syracuse, NY USA State Univ New YorkUpstate Med Univ Syracuse NY USA v, Syracuse, NY USA
Titolo Testata:
JOURNAL OF IMMUNOTHERAPY
fascicolo: 3, volume: 24, anno: 2001,
pagine: 205 - 211
SICI:
1524-9557(200105/06)24:3<205:AEOMRC>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
FACTOR PLUS INTERLEUKIN-4; NECROSIS-FACTOR-ALPHA; RECOMBINANT INTERLEUKIN-2; REDUCED TUMORIGENICITY; DOSE INTERLEUKIN-2; GENE-TRANSFER; IMMUNITY; CANCER; VACCINATION; EXPRESSION;
Keywords:
renal cell carcinoma; tumor vaccine; granulocyte; macrophage; colony-stimulating factor; interleukin-6;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Nishisaka, N Osaka City Univ, Sch Med, Dept Urol, Abeno Ku, 1-4-3 Asahimachi, Osaka 5438585, Japan Osaka City Univ 1-4-3 Asahimachi Osaka Japan 5438585 , Japan
Citazione:
Y. Kinoshita et al., "Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells", J IMMUNOTH, 24(3), 2001, pp. 205-211

Abstract

The authors evaluted the efficacy of vaccination with murine renal cell carcinoma (Renca) secreting the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene and interleukin-6 (IL-6) gene for the treatment of Renca tumor. Murine GM-CSF and murine IL-6 genes were introduced and expressed inRenca cells (Renca-GM-CSF and Renca-IL-6). For a prevaccination study, wild-type Renca cells were injected subcutaneously into Balb/c mice that had been vaccinated three times with inactivated wild-type Renca, Renca-GM-CSF, Renca-IL-6, or a mixture of Renca-GM-CSF and Renca-IL-6 cells 7, 14, and 21days before this tumor inoculation. For vaccination experiments, Renca tumor-bearing (8 to 10 mm) mice were injected subcutaneously weekly for 3 weeks with inactivated wild-type Renca cells, or either one or a combination ofRenca-GM-CSF and Renca-IL-6. A nonvaccinated control was included in all experiments. The animals were monitored for survival and tumor development for 8 weeks. Mice inoculated with wild-type Renca alone died from the tumor within 35 days. Renca-IL-6 grew slower than wild-type Renca (p < 0.05). No tumor was produced by Renca-GM-CSF. Prevaccination with the combination of Renca-GM-CSF and Renca-IL-6 prevented subsequently inoculated wildtype Renca from forming tumors, and prevaccination with either one of them, comparedwith prevaccination with wild-type Renca, retarded tumor growth and prolonged survival time. Tumor-bearing mice vaccinated with wild-type Renca died within 42 days. Vaccination with Renca-GM-CSF or Renca-IL-6 alone prolongedthe survival time, but only Renca-GM-CSF drastically reduced the tumor size. Vaccination with the combination of them achieved complete remission. Neither of the cytokine-secreting cells enhanced the expression of MHC class I or II molecules. Autologous tumor cell vaccine secreting GM-CSF is effective in preventing and treating established tumors. Its efficacy is enhancedby the cosecretion of IL-6.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 13:32:46